Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 13
1963 5
1964 6
1965 3
1966 5
1967 3
1968 4
1969 5
1970 8
1971 4
1972 3
1973 4
1974 10
1975 6
1976 3
1977 7
1978 19
1979 18
1980 20
1981 19
1982 14
1983 17
1984 32
1985 19
1986 22
1987 18
1988 21
1989 26
1990 28
1991 27
1992 22
1993 24
1994 28
1995 23
1996 27
1997 13
1998 20
1999 35
2000 20
2001 30
2002 28
2003 25
2004 23
2005 31
2006 29
2007 28
2008 28
2009 21
2010 31
2011 41
2012 53
2013 82
2014 77
2015 87
2016 95
2017 113
2018 101
2019 99
2020 120
2021 133
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,785 results
Results by year
Filters applied: . Clear all
Page 1
Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Blair HA. Blair HA. Drugs. 2021 Apr;81(6):709-719. doi: 10.1007/s40265-021-01518-w. Epub 2021 Apr 19. Drugs. 2021. PMID: 33871819 Review.
Indacaterol/glycopyrronium/mometasone was generally well tolerated, and the most common adverse events were respiratory in nature. ...Indacaterol/glycopyrronium/mometasone was generally well tolerated. The most common adverse events were respiratory-related. ...
Indacaterol/glycopyrronium/mometasone was generally well tolerated, and the most common adverse events were respiratory in nature. .. …
Glycopyrronium/Formoterol: A Review in COPD.
Al-Salama ZT, Frampton JE. Al-Salama ZT, et al. Drugs. 2019 Sep;79(13):1455-1466. doi: 10.1007/s40265-019-01186-x. Drugs. 2019. PMID: 31468315 Review.
Glycopyrronium/formoterol (Bevespi Aerosphere()) is a fixed-dose combination of the long-acting muscarinic antagonist glycopyrronium bromide and the long-acting beta(2)-agonist formoterol fumarate delivered via a pressurized metered dose inhaler (pMDI) and formulate
Glycopyrronium/formoterol (Bevespi Aerosphere()) is a fixed-dose combination of the long-acting muscarinic antagonist glycopyrroni
Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK. Nwannunu CE, et al. Skin Therapy Lett. 2019 Mar;24(2):1-3. Skin Therapy Lett. 2019. PMID: 30970203 Free article. Review.
In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown to be an effective, safe and non-invasive treatment for patients suffering from primary hyperhidrosis. This review examines the clinical tri …
In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown …
Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA. Heo YA. Drugs. 2021 Aug;81(12):1411-1422. doi: 10.1007/s40265-021-01562-6. Epub 2021 Aug 3. Drugs. 2021. PMID: 34342835 Free PMC article. Review.
In two pivotal phase III trials of 24-52 weeks' duration, budesonide/glycopyrronium/formoterol reduced the rates of moderate/severe COPD exacerbations and improved lung function to a greater extent than budesonide/formoterol and/or glycopyrronium/formoterol. ...Bude …
In two pivotal phase III trials of 24-52 weeks' duration, budesonide/glycopyrronium/formoterol reduced the rates of moderate/severe C …
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting beta(2)-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E. Ferguson GT, et al. Adv Ther. 2020 Jun;37(6):2956-2975. doi: 10.1007/s12325-020-01311-3. Epub 2020 Apr 25. Adv Ther. 2020. PMID: 32335859 Free PMC article.
INTRODUCTION: Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta(2)-agonist (ICS/LAMA/LABA) combination therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who experience further exacerbations/symptoms on dual LAMA/L …
INTRODUCTION: Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta(2)-agonist (ICS/LAMA/LABA) combination therap …
Glycopyrronium for COPD.
[No authors listed] [No authors listed] Drug Ther Bull. 2013 Jun;51(6):66-8. doi: 10.1136/dtb.2013.6.0184. Epub 2013 Jun 6. Drug Ther Bull. 2013. PMID: 23744364 Review.
Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).1 This is the third
Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Virchow JC, et al. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. Lancet. 2019. PMID: 31582314 Clinical Trial.
Here we report on two studies that compared the single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting beta(2) agonist), and glycopyrronium (G; long-acting muscarinic antagonist) with the combi …
Here we report on two studies that compared the single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticoster …
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Banerji D, Fogel R, Patalano F. Banerji D, et al. Drug Discov Today. 2018 Jan;23(1):196-203. doi: 10.1016/j.drudis.2017.10.015. Epub 2017 Oct 24. Drug Discov Today. 2018. PMID: 29079130 Review.
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). ...
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting beta(2)-agonist (LABA)/long-acting muscarinic an …
Glycopyrrolate.
Mirakhur RK, Dundee JW. Mirakhur RK, et al. Gen Pharmacol. 1981;12(6):423-7. doi: 10.1016/0306-3623(81)90064-1. Gen Pharmacol. 1981. PMID: 7030865 Review. No abstract available.
1,785 results